Coprocessing of kininogens by a mixture of human mast cell tryptase and neutrophil elastase was explored as a potential substitute for the kallikrein-dependent pathway for kinin generation during inflammation. Tryptase easily excised bradykinin from the synthetic heptadecapeptide, ISLMKRPPGFSPFRSSR, but was unable to produce significant amounts of kinin by proteolysis of kininogens. However, a mixture of tryptase and elastase released bradykinin from each protein with a yield comparable to that of human plasma kallikrein. Significantly, neither plasma nor tissue kallikrein was able to effectively process N-chlorosuccinimide-oxidized high molecular weight kininogen, an effect attributed to the oxidation of a methionine residue upstream from the N terminus of the kinin domain. In support of these results the model heptadecapetide, ISL(MO)KRP-PGFSPFRSSR, was also resistant to hydrolysis by either kallikrein. In contrast, the release of bradykinin from oxidized peptide or protein substrates by the tryptase/ elastase mixture was not altered. Because kininogen modification may occur at inflammatory sites, as a result of the oxidative burst of recruited neutrophils and macrophages, these results suggest an alternative pathway for kinin production and the necessity for the novel utilization of two specific proteinases known to be released from these cells during inflammatory episodes.
Mast cells are distributed in the body near surfaces exposed to the external environment. They are believed to contribute to the first line of host defense against bacterial or parasite infection through the release of an array of proinflammatory mediators after stimulation (1) (2) (3) (4) . Included among these factors is a trypsin-like serine proteinase, tryptase, the predominant protein constituent of all types of mast cells and the sole proteinase of human lung mast cell type MC T (4, 5) . Although the enzymatic and molecular properties of tryptase are far better characterized than any of its plausible biological functions (6) , it is clear that this enzyme prefers peptides rather than proteins as substrates (6, 7) , with vasoactive intestinal peptide (8) and the calcitonin gene-related peptide (9) being two of the best potential physiological tryptase targets. Nevertheless, the processing of some protein substrates by tryptase has been suggested from in vitro studies, including fibrinogen and fibronectin degradation (10 -12) , prostromelysin activation (13) , and slow generation of anaphylatoxin C3a (14) and kininogen fragmentation (8, (15) (16) (17) (18) , with the latter study indicating the possible effect of this enzyme on activation of the kinin pathway.
The term kinin is a collective name for bradykinin (BK) 1 and a few related bioactive peptides capable of generating all of the classic symptoms of inflammation, including fever, redness, edema, and pain (19, 20) . In particular, BK is known to be produced during nasal allergen exposure (21, 22) , where it binds to human nasal mucosa (23) and evokes severe bronchoconstriction during asthma (24) . The bradykinin structure within the kininogen sequence . . .ISLMKRPPGFSPFRSSR. . . is characterized by two features. First, excision of BK clearly indicates the requirement for at least one trypsin-like activity to cleave at two sites, processes normally performed by the degradation of high molecular weight kininogen (HMWK) by plasma kallikrein; another, 1-residue-longer kinin, kallidin (Lys-BK), can be produced by tissue kallikrein from both HMWK and low molecular weight kininogen (LMWK) (25) . Second, a methionine residue is present just upstream from the first cleavage sites shown above, which, if oxidized, could affect kinin production by either or both of the kallikrein enzymes.
It is already well known that a third kinin, Met-Lys-BK, can be produced by the concerted action of kallikrein and human neutrophil elastase (HNE) so that the involvement of two enzymes to produce kinins is certainly possible (26, 27) . Recently, it was noted that tryptase could release kinins from both HMWK and LMWK, in addition to activating prekallikrein (18) , although the amounts of bioactive peptide produced were unlikely to be of physiological significance. Because oxidative processes are routinely occurring at inflammatory sites (28), we hypothesize that because the presence of a methionine residue in the proximity of the cleavage site, normal kininogen processing may be affected, so that alternative pathways would have to be invoked to ensure kinin release. Functional changes have frequently been suggested to occur in proteins with oxidation-sensitive amino acid residues located at or near the sites of specific interaction with other proteins (29) . Because mast cells, macrophages, and neutrophils are recruited to such affected sites where they release oxidants and/or proteinases (30, 31) , it is our contention that a mixture of such hydrolytic enzymes secreted by these cells could be used to maintain kinin production during inflammatory episodes.
In this study, we describe the effective release of BK from both a model, kinin-containing peptide by tryptase and from HMWK or LMWK by mixtures of tryptase and HNE. In addition, we show that kinin production after substitution of methionine sulfoxide for methionine in the model peptide or by oxidation of kininogens is not affected with the tryptase/HNE mixtures, but it is markedly reduced when exposed to either plasma or tissue kallikrein.
EXPERIMENTAL PROCEDURES
Chemicals-Model kinin-containing heptadecapeptides, ISL(M or MO)KRPPGFSPFRSSR (MO, methionine sulfoxide, the diastereoisomeric mixture), were synthesized at the Molecular Genetics Instrumental Facility (University of Georgia) using the standard Fmoc (N-(9-fluorenyl)methoxycarbonyl) protocol with an Advanced ChemTech MPS350 automated synthesizer. BK, Lys-BK, and Met-Lys-BK were from Sigma; sequanal grade trifluoroacetic acid (TFA) was from Pierce; and HPLC grade methanol and acetonitrile were from Fisher.
Proteins and Enzymes-Single-chain HMWK was obtained from Enzyme Research Laboratories (South Bend, IN), and LMWK and human plasma kallikrein were from Athens Research and Technology (Athens, GA). Human lung tryptase (18) , HNE (32), and human neutrophil cathepsin G (32) were purified as described previously. Human recombinant chymase was a gift of Axys Pharmaceutical (San Francisco, CA), and porcine pancreas kallikrein was graciously provided by Prof. Hans Fritz (University of Munich, Munich, Germany).
Oxidation of HMWK-HMWK (8.5 M) in 20 mM HEPES buffer, pH 7.4, was incubated with a 100-fold molar excess of N-chlorosuccinimide (33) for 2 h at 37°C; the reaction was then quenched with 6 mM methionine for 0.5 h at 37°C.
Determination of Time Course and Pattern for the Proteolytic Cleavage of Model Kinin-containing Heptadecapeptides-Both methionineand methionine sulfoxide-containing model peptides (M-pep and MOpep, respectively), at a concentration of 50 M, were treated with tryptase or kallikreins at various concentrations in 25 mM HEPES buffer, pH 7.0, at 37°C. The buffer was supplemented with heparin (2 units/ml) whenever tryptase was used. The reaction was stopped by mixing with a 0.1 volume of 6 N HCl.
For following the time course of substrate decay and formation of major cleavage products, samples obtained after various incubation times were analyzed by reverse-phase HPLC using a Beckman liquid chromatograph consisting of two 110B pumps, 166 UV detector, 406 analog interface, and System Gold version 6.01 software. Samples were centrifuged (10,000 ϫ g, 2 min), and 50-l aliquots were loaded onto a Beckman Ultrasphere 5-m ODS column (4.6 ϫ 250 mm) equipped with an Ultrasphere 5 m ODS guard column (4.6 ϫ 45 mm). Solvent A was 0.1% TFA in water, and solvent B was 0.08% TFA in 80% acetonitrile/ water; both were filtered through Nylaflo 0.45-m filter (Gelman Sciences, Ann Arbor, MI) and vacuum-degassed before use. The separation was performed with a linear gradient from 10 to 100% solvent B, which was developed over 40 min at a flow rate of 1 ml/min; the elution was monitored at 215 nm.
The major cleavage products were identified by separation of the digestion mixtures (20 l) on an Ashipac 5 m ODP C18 column (1 ϫ 200 mm; Keystone Scientific, Bellefonte, PA) with a gradient elution (solvent A, 0.1% TFA/water; solvent B, 0.1% TFA, 80% acetonitrile; 0 -100% solvent B in 60 min at a flow rate of 40 l/min) using an Applied Biosystems liquid chromatograph (140B solvent delivery system and Applied Biosystems 759A absorbance detector) coupled to on-line atmospheric pressure ionization mass spectrometry with a PESciex API1 Plus mass spectrometer. This liquid chromatographic mass spectrometric analysis was done at the Chemical and Biological Sciences Mass Spectrometry Facility (University of Georgia).
Detection and Time Course of Proteolytic Release of Kinins from
Kininogens-Native and oxidized forms of either HMWK (1 M) or LMWK (3 M) in 25 mM HEPES buffer, pH 7.0, were incubated with selected proteinases or proteinase mixtures (each enzyme at 0.1 M concentration) at 37°C. Whenever tryptase or chymase was used, the buffer was supplemented with heparin (2 units/ml). To stop the reaction, aliquots of the incubation sample were mixed with 0.1 volume of 6 N HCl.
For the detection of kinins, the samples were analyzed by reverse phase HPLC using the Beckman chromatograph specified above, with isocratic elution in 0.1% TFA, 35% methanol/water at a flow rate of 1 ml/min and detection at 215 nm. In this solvent/column system, the three major kinins, BK, Lys-BK, and Met-Lys-BK, could be completely separated with retention times of ϳ16.5, 12, and 19 min, respectively, and a lower detection limit of 10 ng for each compound.
Some of the peptide peaks, which eluted within the kinin window, i.e. of retention times within the range 10 -25 min, were collected and subjected to sequence analysis, which was performed at the Molecular Genetics Instrumental Facility using an Applied Biosystems Procise sequencer.
RESULTS

Cleavage of Model Kinin-containing Substrates by Kallikreins or Tryptase-
The proteolytic processing of the intact methionine-containing heptadecapeptide (M-pep), ISLMKRP-PGFSPFRSSR, by plasma kallikrein was clearly biphasic. In the first stage, the substrate was rapidly cleaved after Arg 14 releasing the kinin C terminus (Fig. 1A) , whereas the second cleavage after Lys 5 , which completed the BK excision, was much slower and required an increase of kallikrein concentration by 1 order of magnitude to be followed within a comparable time scale (Fig. 1B) . The substitution of methionine sulfoxide for methionine in the peptide substrate had no influence on the rate of cleavage at the Arg 14 -Ser 15 peptide bond by plasma kallikrein (Fig. 1C) . However, this enzyme was, for all practical purposes, unable to complete the release of BK from MO-pep, i.e. to cleave the Lys 5 -Arg 6 bond 1 residue downstream from the methionine sulfoxide residue (Fig. 1D) . A similar picture, with a rapid accumulation of ISLMKRPPGFSPFR intermediate and its much slower processing to release Lys-BK, was obtained with tissue (pancreas) kallikrein ( Fig. 2A) . Indeed, the matching "intermediate" released from MO-pep was essentially trapped (Fig. 2B) .
The M-pep turned out to be an excellent synthetic substrate for tryptase, which could be used at 60 or 100 times lower molar concentration (15 or 25 times in terms of active site concentrations) than either plasma or tissue kallikrein, respectively, to complete the kinin release within the same time scale (Fig. 3A) . Moreover, unlike kallikreins, tryptase began the processing of M-pep by initial cleavage after Lys 5 to release the N terminus of BK. The alternative cleavage after Arg 14 , however, still proceeded at a considerable rate so that, besides accumulation of the predominating 6 -17 peptide, a detectable amount of 1-14 peptide was also noted at the intermediate stages of the reaction. For the cleavage of MO-pep, hydrolysis after Lys 5 by tryptase was moderately slower than that in M-pep (Fig. 3B ) so that both "intermediates" became equivalent. By continued processing of both forms, BK was produced with an overall rate slightly lower but a reaction yield of the same magnitude as with M-pep on a 3-h digestion time scale.
Release of BK from Kininogens by Simultaneous Action of Tryptase and HNE-As shown in Fig. 4A , the incubation of HMWK at a normal plasma concentration (34) under physiological conditions with a mixture of tryptase and HNE (enzyme: substrate ratio, 1:10) resulted in the release of at least two compounds which eluted within the kinin chromatographic window. The major component had a retention time strictly identical to that of a BK standard. When collected and subjected to automated Edman degradation this fraction was readily identified as RPPGFSPFR, an essentially uncontaminated BK. None of the other major kinins, Lys-BK or Met-Lys-BK, was detectable in the eluate. The formation of BK was attributed exclusively to the effects of the mixture of tryptase and HNE, because neither enzyme, alone, was able to release detectable amounts of BK (Fig. 4A) . Also, no kinin forms could be detected with the chromatographic method used when HNE was replaced by other major proteinases of mast cells (chy-mase) or neutrophils (cathepsin G) in the mixture with tryptase (results not shown). Within the limit of this HPLCspectrophotometric detection, specified under "Experimental Procedures," one can calculate that none of the other enzyme systems tested was able to generate kinins in a yield exceeding 10% of "productively" cleaved kininogen molecules. A similar picture was obtained with LMWK as a substrate (Fig. 4B) , with the BK formed by tryptase/HNE mixture again being identified by its retention time and sequence.
Significantly, the production of BK from HMWK by the tryptase/HNE mixture was quite effective in comparison with the primary natural BK-releasing system, which used plasma kallikrein (Fig. 5A) ; although the rate was only 3-4 times slower, the yield of BK was comparable for both enzyme systems within a reasonable time scale. 
FIG. 2. Time course for cleavage of kinin-containing heptadecapeptides ISLMKRPPGFSPFRSSR (A) and ISL(MO)KRPPGF-SPFRSSR (B) by porcine pancreas kallikrein. Substrates (50 M)
were incubated with a 0.357 M concentration of this tissue kallikrein (1:10 mass enzyme:substrate ratio).
FIG. 3. Time course for cleavage of kinin-containing heptadecapeptides, ISLMKRPPGFSPFRSSR (A) and ISL(MO)KRPPGF-SPFRSSR (B) by human lung tryptase.
Incubation conditions: 25 mM HEPES buffer, pH 7.0, with heparin (2 units/ml), 37°C, 50 M substrate, 3.73 nM enzyme (1:200 mass enzyme:substrate ratio). After specified times, the incubation mixtures were analyzed by a gradient HPLC; the major eluting components were identified by atmospheric pressure ionization mass spectrometry.
The effects of either variable tryptase or HNE concentration on BK release from HMWK when the other enzyme in the mixture was fixed at an enzyme:substrate molar ratio of 1:10 M are shown in Fig. 5B . Between 10 and ϳ150 nM, the yield of BK was clearly dependent on the concentration of HNE rather than that for tryptase.
Kinin Release from Oxidized HMWK by Kallikreins or Tryptase/HNE Mixture-After modification of HMWK with N-chlorosuccinimide, a reagent reported to preferentially oxidize methionine residues in proteins (33), the preparations that were obtained turned out to be a very poor source of kinin production in response to treatment with either plasma kallikrein (Fig. 6A) or tissue (pancreas) kallikrein (Fig. 6B) . However, and in sharp contrast, the tryptase/HNE mixture could readily release BK from oxidized HMWK and just as effectively as from the intact substrate (Fig. 7) .
DISCUSSION
Although a previous report from our laboratory suggested that a considerable amount of BK could be released from both HMWK and LMWK (18) , by tryptase digestion, the present work indicates that the production of this kinin by this process does not exceed the yield of 10% "productively" cleaved kininogen molecules. However, tryptase easily excises BK from a model heptadecapeptide containing the kinin sequence, the result consistent with the well known preference of this enzyme for peptide rather than protein substrates (6, 7) . It is thus very likely that once such peptides are formed as products of kininogen fragmentation by a non-trypsin-like proteinase functioning at the inflammatory site, tryptase can quickly process these fragments to release BK. The present model study clearly suggests HNE as a tryptase partner for the hypothetical collaborative kinin release from kininogens. Indeed, both enzymes in a mixture are capable of producing BK from HMWK and LMWK, with an efficiency not much lower than that of the kallikreins that were used as reference kinin-generating systems. Because BK is the only kinin detectable, tryptase must release the N terminus of this kinin with a rate much faster than that for the alternative upstream cleavages by HNE, which might result in the production of Lys-BK or Met-Lys-BK. These forms of kinins are likely to be formed in vivo by concerted action of HNE and kallikreins because kininogen degradation by elastase either does not affect (35) or even possibly stimulates (26) kinin activity generation by plasma kallikrein. In this case, however, because of the relatively slow processing of kininogen fragments by kallikrein at the N terminus of the bradykinin sequence, apparent from our studies using the model heptadecapeptide, accumulation of Lys-BK and MetLys-BK would occur. Indeed, this assumption is confirmed by the presence of Met-Lys-BK in pathophysiological fluids (36). In this regard HNE/kallikrein coupling may represent a backup system to generate kinin activity in an environment of elevated nonspecific proteolytic activity. From our present study it is apparent that similar function of kinin generation in specific pathological conditions may be carried on by the mixture of HNE and tryptase, the major mast cell proteinase.
The currently emerging concept of a central role of mast cells in natural immunity as well as their significant contribution to acquired immunity (1-3, 37) goes far beyond the traditional recognition of the rather detrimental action of these cells after activation by IgE-antigen complexes that occurs in the pathogenesis of asthma, anaphylaxis, and other allergic responses (4). The explosive, "anaphylactic" (38) degranulation of mast cells as the primary event in these diseases leaves little to chance that neutrophil-or macrophage-derived proteinases could join with mast cell enzymes for the fruitful coprocessing of biological substrates freely available in the medium, particularly kininogens which, are ubiquitously distributed in body fluids. However, the slower reaction of mast cells, associated with a rather gradual, "piecemeal" (38) degranulation, is well known and has been implicated as an important factor in some chronic diseases, including rheumatoid arthritis, stress-induced intestinal ulceration, interstitial cystitis, scleroderma, and Crohn's disease (3) . In these specific pathological conditions neutrophils are also abundant at the lesion sites (39 -45) , and it is now apparent that mast cells may actively participate in phagocyte accumulation through their release of the neutrophil-attracting CXC chemokines, including interleukin 8 (46) . In this way the random degranulation of mast cells, which are long-lived and may experience several degranulation events during their life span (3), can occur simultaneously with chemokine-stimulated release of elastase from activated neutrophils. This event thus brings together both proteinases for concerted action on kininogens supplied in plasma exudate induced by increased vascular permeability originally caused by histamine release and perpetuated by locally generated kinins. Indeed, a vast body of literature indicates that at least in synovial fluid both elastase and tryptase coexist (47) (48) (49) (50) (51) (52) (53) , and the presence of fibrinogen-and IgG-derived fragments in this fluid (49, 54) indicates that the HNE-catalyzed degradation of functional proteins can occur under in vivo conditions.
The acute inflammatory lesions caused by bacterial infections represent another pathological environment where tryptase and elastase could be operating in concert. In this case innate defense reactions of the complement system activation pathways would lead to release of C5a anaphylatoxin, which is known to induce both neutrophil activation, accompanied by release of lysosomal enzymes, including elastase, as well as degranulation of mast cells (55) . The existence of such a scenario is strongly supported by the presence of mast cells and neutrophil proteolytic enzymes in edema fluid, the inflammatory exudate at the site of bacterial infection (56 -59) . Simultaneous degranulation of both types of cells must also occur in chronic inflammatory diseases, because both elastase and tryptase have been found in bronchial tissues and bronchial lavage fluid from patients with chronic bronchitis (60 -63) .
The efficacy of BK release by the HNE and tryptase pair depends on the relative concentration of both proteinases operating in this system. From results presented in Fig. 3B it is apparent that at 0.1 M elastase concentration, the effective tryptase concentration is as low as 1 nM. Tryptase, at this or even higher levels, has been found in several pathophysiological fluids, including allergic nasal lavages (64), synovial fluid (50) , and the plasma of patients who died of anaphylaxis (65) .
In contrast to tryptase, which is not controlled by any of the endogenous proteinase inhibitors (66), HNE activity is tightly regulated by ␣ 1 -proteinase inhibitor (␣ 1 -PI) (67) , and, consequently, it is unlikely that under physiological conditions this enzyme concentration can reach high enough levels for effective collaboration with tryptase to release BK form HMWK. However, the active site methionine residue in ␣ 1 -PI is very susceptible to oxidation to methionine sulfoxide, rendering the inhibitor inactive against its physiological target (68 -70). Under in vivo conditions large amounts of oxidants are released from phagocytes at the inflammatory sites in the host-defense response against invading microorganisms. Most of this activity is attributed to macrophages and neutrophils (28) , but, recently, the mast cells have also been shown to be able to phagocytize bacteria (71, 72) and to release reactive oxygen species (72) . All of these inflammatory oxidative processes are primarily used to kill foreign organisms. However, host proteins that are sensitive to oxidation, as exemplified by ␣ 1 -PI and plasminogen activator inhibitor-1, may also be affected so that they are no longer functional, and this can result in the exacerbation of the inflammatory response.
From our studies kininogens appear as other proteins with functions that could be damaged by oxidative modification. We explain this by the fact that, at least in vitro, the HMWK susceptibility to oxidation, as measured by inability to be used as a source of kallikreins-generated kinins, is comparable with that for the oxidative inactivation of ␣ 1 -PI (data not shown). Because the latter protein has been found in an oxidized form in both human rheumatoid synovial fluid (73) and in lung washings from cigarette smokers (74) , it is assumed that oxidized HMWK could also be produced at local inflammatory sites. From comparative studies with the model kinin-containing heptadecapeptide with or without the methionine sulfoxide residue just upstream from the N terminus of kinin domain, it is easily demonstrated that processing at this site is markedly reduced with MO-pep, and we propose that this residue is also a subject of oxidative modification in HMWK. This decrease in the ability to cleave oxidized protein or peptide substrates by kallikreins is in keeping with the known requirement of plasma or tissue kallikrein for a hydrophobic residue at either the P 2 or P 1 position, respectively.
In summary, our results together with previously established data from the literature suggest that an alternative pathway for the generation of kinins by the cooperative action of mast cell tryptase and HNE may operate in vivo under the oxidative environment of inflammatory sites. This pathway is likely to compensate for the lost ability to release kinins from oxidized kininogens by the kallikrein system. Undisturbed, local kinin generation may have important physiological functions for control of the inflammatory reaction, because, through enhancement of vascular permeability, it allows increased extravasation of plasma proteinase inhibitors, including ␣ 1 -PI, ␣ 1 -anti-chymotrypsin, and ␣ 2 -macroglobulin, which are instrumental for controlling excessive proteolytic activity and, therefore, protecting against connective tissue damage.
